EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease

Jack M Chapel iD, Bryan Tysinger, Hossein Pourmand, Dana Goldman, Paul Aisen, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.10.2026. Verfasst von Jack M Chapel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sol Price School of Public Policy, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, USC Schaeffer Center for Health Policy & Economics, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier. RESULTS Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality‐of‐life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4‐year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION Timely treatment consistently increased long‐term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansDisease ProgressionAgedFemaleTreatment DelayQuality of LifeUnited StatesMaleHealth Care CostsCost-Benefit Analysis

Stichwörter der Autor:innen

Alzheimer's diseaseanti‐amyloid therapycare pathwaydonanemabmicrosimulationsocial value

Autor:innen und Institutionen

  • Sol Price School of Public Policy, University of Southern California, Los Angeles, California, USA.
  • Leonard D. Schaeffer Institute for Public Policy and Government Service, University of Southern California, Los Angeles, California, USA.
  • Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
  • Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Jack M Chapel

Förderung

  • NIA NIH HHS
  • USC Schaeffer Center for Health Policy & Economics
  • National Institute on Aging

Zitieren

APA

Chapel, J. M., Tysinger, B., Pourmand, H., Goldman, D., Aisen, P., & Alzheimer's Disease Neuroimaging Initiative (2026). The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71819

Vancouver

Chapel JM, Tysinger B, Pourmand H, Goldman D, Aisen P, Alzheimer's Disease Neuroimaging Initiative. The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71819

BibTeX
@article{Chapel2026,
  author = {Chapel, Jack M and Tysinger, Bryan and Pourmand, Hossein and Goldman, Dana and Aisen, Paul and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {10},
  doi = {10.1002/alz.71819}
}
Kostenlos starten →